ANI Total Other Income Expense Net from 2010 to 2025

ANIP Stock  USD 67.61  0.75  1.10%   
ANI Pharmaceuticals Total Other Income Expense Net yearly trend continues to be relatively stable with very little volatility. Total Other Income Expense Net is likely to drop to about -23.9 M. During the period from 2010 to 2025, ANI Pharmaceuticals Total Other Income Expense Net destribution of quarterly values had r-value of (0.87) from its regression line and median of (4,328,468). View All Fundamentals
 
Total Other Income Expense Net  
First Reported
2000-09-30
Previous Quarter
-11 M
Current Value
-9.4 M
Quarterly Volatility
B
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check ANI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ANI Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 71.1 M, Interest Expense of 18.5 M or Selling General Administrative of 262.1 M, as well as many indicators such as Price To Sales Ratio of 1.65, Dividend Yield of 0.0012 or PTB Ratio of 2.37. ANI financial statements analysis is a perfect complement when working with ANI Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of ANI Pharmaceuticals Correlation against competitors.
To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

Latest ANI Pharmaceuticals' Total Other Income Expense Net Growth Pattern

Below is the plot of the Total Other Income Expense Net of ANI Pharmaceuticals over the last few years. It is ANI Pharmaceuticals' Total Other Income Expense Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ANI Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Total Other Income Expense Net10 Years Trend
Slightly volatile
   Total Other Income Expense Net   
       Timeline  

ANI Total Other Income Expense Net Regression Statistics

Arithmetic Mean(9,565,080)
Coefficient Of Variation(111.82)
Mean Deviation9,207,780
Median(4,328,468)
Standard Deviation10,695,808
Sample Variance114.4T
Range27.6M
R-Value(0.87)
Mean Square Error28.8T
R-Squared0.76
Slope(1,964,673)
Total Sum of Squares1716T

ANI Total Other Income Expense Net History

2025-23.9 M
2024-22.8 M
2023-27.1 M
2022-27.4 M
2021-16.3 M
2020-9.9 M
2019-13.2 M

About ANI Pharmaceuticals Financial Statements

ANI Pharmaceuticals shareholders use historical fundamental indicators, such as Total Other Income Expense Net, to determine how well the company is positioned to perform in the future. Although ANI Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in ANI Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on ANI Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Total Other Income Expense Net-22.8 M-23.9 M

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.